Get the Stockscreener App
3.02
3.07%
0.09
After Hours:
3.22
0.20
+6.62%
Adagene Inc Adr stock is traded at $3.02, with a volume of 53,270.
It is up +3.07% in the last 24 hours and up +18.90% over the past month.
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development, and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity, as highlighted by the company's immunotherapy pipeline.
See More
Previous Close:
$2.93
Open:
$2.9
24h Volume:
53,270
Relative Volume:
0.47
Market Cap:
$142.34M
Revenue:
$18.11M
Net Income/Loss:
$-18.95M
P/E Ratio:
-6.9029
EPS:
-0.4375
Net Cash Flow:
-
1W Performance:
-2.74%
1M Performance:
+18.90%
6M Performance:
+37.27%
1Y Performance:
+47.32%
1-Day Range:
$2.80
$3.035
1-Week Range:
$2.7801
$3.20
52-Week Range:
$1.30
$3.53
Adagene Inc Adr Stock (ADAG) Company Profile
Compare ADAG vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ADAG
Adagene Inc Adr
|
3.02 | 138.09M | 18.11M | -18.95M | 0 | -0.4375 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Adagene Inc Adr Stock (ADAG) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-24-25 | Initiated | Guggenheim | Buy |
| Aug-06-25 | Initiated | Leerink Partners | Outperform |
| Jan-31-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-25-21 | Initiated | China Renaissance | Buy |
| Mar-08-21 | Initiated | Goldman | Buy |
| Mar-08-21 | Initiated | Jefferies | Buy |
| Mar-08-21 | Initiated | Morgan Stanley | Overweight |
View All
Adagene Inc Adr Stock (ADAG) Latest News
Adagene Inc. Sponsored ADR (NASDAQ:ADAG) Short Interest Down 24.5% in February - MarketBeat
Adagene Spotlights ADG126+KEYTRUDA Data, Late-Line MSS-CRC Focus in Oppenheimer Conference Talk - MarketBeat
Comparing KALA BIO (NASDAQ:KALA) and Adagene (NASDAQ:ADAG) - Defense World
Adagene to Participate in Two Upcoming Investor Conferences - The Manila Times
Adagene sets Oppenheimer, Leerink fireside chats for Feb. 25, March 9 - Stock Titan
Moderna's Shares Climb 5.3% as Investors Revisit Biotech Leaders - TradingView
Short Interest in Adagene Inc. Sponsored ADR (NASDAQ:ADAG) Rises By 283.2% - Defense World
Short Interest in Adagene Inc. Sponsored ADR (NASDAQ:ADAG) Expands By 283.2% - MarketBeat
Short Interest in Adagene Inc. Sponsored ADR (NASDAQ:ADAG) Drops By 31.1% - MarketBeat
Adagene Inc. Sponsored ADR (NASDAQ:ADAG) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Adagene Inc. Sponsored ADR (NASDAQ:ADAG) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
Adagene Provides Business Update and 2026 Objectives - The Manila Times
Short Interest in Adagene Inc. Sponsored ADR (NASDAQ:ADAG) Rises By 48.9% - MarketBeat
Total debt per share of Adagene, Inc. Sponsored ADR – LS:A2QN45 - TradingView — Track All Markets
Adagene Inc. Sponsored ADR (NASDAQ:ADAG) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Short Interest in Adagene Inc. Sponsored ADR (NASDAQ:ADAG) Declines By 36.8% - MarketBeat
Analysts Set Expectations for Adagene FY2025 Earnings - Defense World
Analysts Issue Forecasts for Adagene FY2025 Earnings - MarketBeat
FDA Grants Fast Track Designation to ADAG's Colorectal Cancer Drug - The Globe and Mail
Adagene, Palvella up after FDA Fast Track tags (ADAG:NASDAQ) - Seeking Alpha
Adagene stock soars after FDA grants Fast Track status for cancer therapy - Investing.com Nigeria
Adagene stock soars after FDA grants Fast Track status for cancer therapy By Investing.com - Investing.com South Africa
FDA grants fast track status to Adagene’s muzastotug for colorectal cancer - Investing.com
FDA grants fast track status to Adagene’s muzastotug for colorectal cancer By Investing.com - Investing.com South Africa
Adagene Announces FDA Fast Track Designation for Muzastotug (ADG126) - GlobeNewswire
Adagene Inc. Sponsored ADR (NASDAQ:ADAG) Receives $7.67 Consensus Target Price from Analysts - Defense World
Adagene (NASDAQ:ADAG) Earns Buy Rating from Analysts at Guggenheim - Defense World
Adagene (NASDAQ:ADAG) Now Covered by Guggenheim - MarketBeat
Get in on Adagene Inc ADR’s (ADAG) buy-in window today! - Setenews
Can Adagene Inc. Depositary Receipt stock double in next 5 years2025 Price Action Summary & Weekly Consistent Profit Watchlists - newser.com
Adagene Inc. Sponsored ADR (NASDAQ:ADAG) Receives $7.00 Average Target Price from Analysts - Defense World
Adagene (NASDAQ:ADAG) Upgraded at Lifesci Capital - Defense World
Adagene Announces Licensing Agreement with Third Arc Bio for Development of Two Masked CD3 T Cell Engagers Utilizing SAFEbody® Technology - wahanariau.com
Adagene and Third Arc Bio Forge Licensing Agreement for Cancer Therapy Development - TipRanks
Adagene Inc. Announces Licensing Agreement with Third Arc Bio to Utilize SAFEbody Technology for CD3 T Cell Engagers - Quiver Quantitative
Adagene Announces Licensing Agreement with Third Arc Bio - GlobeNewswire
Why Adagene Inc. Depositary Receipt stock is in analyst buy zoneTrade Performance Summary & Weekly High Potential Alerts - newser.com
Why Adagene Inc. Depositary Receipt stock is a must watch in 2025Weekly Loss Report & Reliable Trade Execution Plans - newser.com
What’s the recovery path for long term holders of Adagene Inc. Depositary ReceiptExit Point & High Win Rate Trade Alerts - newser.com
Adagene Inc. Depositary Receipt stock daily chart insightsQuarterly Earnings Summary & Target Return Focused Stock Picks - newser.com
Understanding Adagene Inc. Depositary Receipt’s price movement2025 Market Outlook & Community Supported Trade Ideas - newser.com
Adagene doses first patient in Phase 2 trial of muzastotug for MSS CRC - Investing.com India
[F-3] Adagene Inc. Foreign Issuer Shelf Registration | ADAG SEC FilingForm F-3 - Stock Titan
Adagene Inc Adr Stock (ADAG) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.69%
0.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):